

Saskatchewan Immunization Manual Amendments September 2020

Instructions: Please remove and discard the corresponding pages in each chapter section as applicable and insert the amended pages as noted below in each corresponding chapter section.

Chapter 4 – Documentation

- Appendix 4.2
 - Many revisions in each category. Please have your staff review carefully.
 - The whole chapter 4 is being sent to assist with printing of Appendix 4.2.

Chapter 5 – Immunization Schedules

- P. 1 Section 1.1 Routine Immunization Schedules for Infants, Children and Adolescents
 - New footnote 12 added for Men-C-C: If Men-C-ACYW-135 has been received ≥ 1 year old, Men-C-C not required.
- P. 5 Section 1.4 Children 1 Year and Older but less than 7 Years Who Present for Immunizations
 - Original footnote #5 removed referring to 2 doses of MMRV required for these children as redundant.
 - Footnotes renumbered from #5 onward.
- P. 6 section 1.5 Children 7 to 17 Years Who Present for Immunizations
 - Reference to Grade 6 students removed from footnote #3.
 - Footnote #6 now references Appendix Refer to Appendix 5.4 Publicly Funded varicella Immunization Eligibility and Panorama Directives.
- P.8 Section 1.7 Recommended Publicly Funded Immunizations for Adults Who Completed a Primary Childhood Vaccine Series
 - Varicella added to the table with reference to Appendix 5.4.
- P. 9 Section 1.8 Publicly Funded Vaccine Eligibility Criteria
 - Men-C-ACYW-135 program start date removed as expectation is to offer appropriate Meningococcal vaccine based on DOB.
- P. 11 Section 2.1 Minimum Intervals for Specific Vaccine Series
 - New footnote #14 added re: Rota vaccine: The first dose can be administered up to and including 14 weeks 6 days.
- P. 17 Section 3.7.2 Guide to Tetanus Prophylaxis un Wound Management
 - The following sentence is present at the end of footnote #3: MHO approval may be required in some jurisdictions, follow local protocol.

Chapter 6 Contraindications and Precautions

- p. 5 Section 4.3 Illness With or Without a Fever
First paragraph now states: Generally, a mild illness, with or without a fever, is not a reason to avoid immunization. However, individuals who have a mild illness, with or without a fever, may be asked to defer their routine immunization based on current COVID-19 screening criteria. A moderate, or severe acute illness, with or without a fever, may be reason to delay immunization.

Chapter 7 – Immunization of Special Populations

- p. 15 Section 3.3 HIV
 - New statement under live vaccines: Rotavirus vaccine may be administered on schedule to infants regardless of their CD4 counts unless another contraindication exists.
- P. 16 Section 3.3A Publicly Funded Vaccines and Immune Globulins 1– Human Immunodeficiency Virus
 - Add to top row first columns to reflect eligibility for Rotavirus vaccines: All routine vaccines excluding MMRV, MMR and Var
- P. 20 Section 3.7.1 High Dose Corticosteroid Therapy

Saskatchewan Immunization Manual Amendments September 2020

- First sentence now states: Only oral high dose systemic steroids interfere with vaccine induced immune responses (e.g., consider persons receiving prednisone equivalent of ≥ 2 mg/kg/day or 20 mg/day if weight > 10 kg, for ≥ 14 days to be immune-suppressed)
- In second paragraph, the original fist bullet is now 2 separate bullets:
 - prednisone equivalent of less than 2 mg/kg/day or less than 20 mg/day if weight > 10 kg;
 - less than 14 days;

Chapter 9 – Management of Biological Products

- Second page of TOC updated last 2 section's page numbers.
- Revised forms:
 - Cold chain break report form page 1
 - Vaccine Wastage report form
 - Vaccine Problem report form

Chapter 10 – Biological Products

- Non-publicly funded influenza vaccines product monograph links updated.
- Adacel-Polio
 - Scenario 4a updated. Interval between doses 1 and 2 is corrected to 1 month. 6-12 months added for scheduling of dose 3.
- Boostrix-Polio
 - . 6-12 months added for scheduling of dose 3.
- Updated product monographs:

Vaqta	Recombivax HB	Menveo	ProQuad	FluLaval tetra
Fluzone Quadrivalent	Fluzone High Dose	GamaSTAN S/D		

Chapter 11 – Adverse Events Following Immunization

- TOC
 - Appendices page numbers revised.
- P. 7 section 3.2
 - AEFI form link updated in #3.
- P. 11 Appendix 11.1 Summary of AEFI Reporting Criteria
 - Table updated as per latest version of the AEFI User Guide.
- P. 12 Appendix 11.2 AEFI Report form
 - Link updated.
- Pp. 13-14 Appendix 11.5 Canadian Biological Product Abbreviations
 - Pages renumbered.

Chapter 14 – Appendices

Appendix 14.3 Immunization fact sheets

- Fact sheets have been revised including product monographs where applicable, a link to the provincial fact sheets has been added; the section regarding Panorama Privacy has been removed; and a new indication regarding deferral of immunization related to COVID-19 symptoms has been added. The revision exception is the *Vaccine Options to Protect your Child from MMR and Var.* fact sheet.
- P. 40: Letter added: HIV Positive or Exposed Infants are Eligible to Receive a Rotavirus Vaccine Series.